Combination therapy with GPX4 inhibitors and anti-PD1 resulted in better tumor suppression and remodeling of tumor microenvironment (TME) compared with monotherapy, suggesting that the combination strategy could be effective in treating tumors with similar biological characteristics to LAR. This evidence concerns the gene PDCD1 and neoplasm.